Stockreport

Key Patent Issues Covering Protagonist Therapeutics' Oral Peptide IL-23 Receptor Antagonists, including the Development Candidate PTG-200

Protagonist Therapeutics, Inc.  (PTGX) 
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.protagonist-inc.com
PDF MILPITAS, Calif., May 4, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that a key patent has issued covering orally stable peptide i [Read more]